Prescription Rejections Surge Amid Weight Loss Drug Costs | Annapolis News

One in three brand-name prescriptions are now initially denied by insurers, a 67% jump since 2018, with nearly half never filled—driven largely by skyrocketing demand for weight-loss drugs like Ozempic and Wegovy, which insurers restrict due to cost. A Johns Hopkins study of 2 million prescriptions reveals insurers are slashing coverage, especially for GLP-1 drugs, which face an 85% rejection rate. As states and insurers impose caps, experts urge drugmakers to negotiate lower prices to restore access and curb costs. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c15aaefb67b7bc2f